Outlook Therapeutics
Outlook Therapeutics Wins FDA Approval, Plus a Copper Strike and a Crypto Lending Launch
Bevacizumab has quietly treated wet macular degeneration off-label for two decades, cheap and effective but never actually built or labeled for the eye. Outlook Therapeutics spent years and two rejected applications trying to close that gap. The FDA signed off on Friday. In Chile a driller pulled 111.9 meters of 0.97% copper out of ground…
